ATE190652T1 - Gentherapie gegen krankheiten die die zellteilung betreffen - Google Patents

Gentherapie gegen krankheiten die die zellteilung betreffen

Info

Publication number
ATE190652T1
ATE190652T1 AT91908358T AT91908358T ATE190652T1 AT E190652 T1 ATE190652 T1 AT E190652T1 AT 91908358 T AT91908358 T AT 91908358T AT 91908358 T AT91908358 T AT 91908358T AT E190652 T1 ATE190652 T1 AT E190652T1
Authority
AT
Austria
Prior art keywords
gene therapy
cell division
against diseases
affect cell
therapy against
Prior art date
Application number
AT91908358T
Other languages
English (en)
Inventor
Yuen Kai Fung
Alan Linn Murphree
Original Assignee
Canji Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Canji Inc filed Critical Canji Inc
Application granted granted Critical
Publication of ATE190652T1 publication Critical patent/ATE190652T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/82—Translation products from oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Toxicology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biotechnology (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Cell Biology (AREA)
  • Plant Pathology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT91908358T 1990-04-10 1991-04-10 Gentherapie gegen krankheiten die die zellteilung betreffen ATE190652T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US50741790A 1990-04-10 1990-04-10
PCT/US1991/002478 WO1991015580A1 (en) 1990-04-10 1991-04-10 Gene therapy for cell proliferative diseases

Publications (1)

Publication Number Publication Date
ATE190652T1 true ATE190652T1 (de) 2000-04-15

Family

ID=24018569

Family Applications (1)

Application Number Title Priority Date Filing Date
AT91908358T ATE190652T1 (de) 1990-04-10 1991-04-10 Gentherapie gegen krankheiten die die zellteilung betreffen

Country Status (18)

Country Link
EP (2) EP0527804B1 (de)
JP (1) JPH05507067A (de)
KR (1) KR100304033B1 (de)
CN (1) CN1057121C (de)
AT (1) ATE190652T1 (de)
AU (3) AU7750191A (de)
CA (1) CA2079903A1 (de)
DE (1) DE69132047T2 (de)
DK (1) DK0527804T3 (de)
ES (1) ES2143463T3 (de)
FI (1) FI924574A0 (de)
GR (1) GR3033695T3 (de)
IE (2) IE20010427A1 (de)
IL (1) IL97774A0 (de)
NO (1) NO923917L (de)
PT (1) PT97316B (de)
WO (1) WO1991015580A1 (de)
ZA (1) ZA912491B (de)

Families Citing this family (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7384735B1 (en) 1986-08-11 2008-06-10 Massachusetts Eye And Ear Infirmary Retinoblastoma nucleic acids
US7223842B1 (en) 1986-08-11 2007-05-29 Massachusetts Eye And Ear Infirmary Detection of proteins whose absence is associated with a neoplasm
US5532220A (en) * 1987-08-31 1996-07-02 The Regents Of The University Of California Genetic mechanisms of tumor suppression
NO312681B1 (no) * 1990-08-24 2002-06-17 Univ California Fremgangsmåte for fremstilling av en farmasöytisk blanding med suppresiv virkning/aktivitet
US5747469A (en) 1991-03-06 1998-05-05 Board Of Regents, The University Of Texas System Methods and compositions comprising DNA damaging agents and p53
CA2108144A1 (en) 1991-03-06 1992-09-07 Jack A. Roth Methods and compositions for the selective inhibition of gene expression
US6410010B1 (en) 1992-10-13 2002-06-25 Board Of Regents, The University Of Texas System Recombinant P53 adenovirus compositions
US5262321A (en) * 1991-05-31 1993-11-16 Dana-Farber Cancer Institute DNA encoding p107 tumor suppressor
WO1993003770A1 (en) * 1991-08-23 1993-03-04 Board Of Regents Of The University Of Nebraska Method and compositions for cellular reprogramming
US6348327B1 (en) 1991-12-06 2002-02-19 Genentech, Inc. Non-endocrine animal host cells capable of expressing variant proinsulin and processing the same to form active, mature insulin and methods of culturing such cells
US5302706A (en) * 1991-12-16 1994-04-12 Baylor College Of Medicine Senescent cell derived inhibitors of DNA synthesis
US6420172B1 (en) * 1992-04-20 2002-07-16 Tib Company, Llc Method for inducing tumor immunity
US5496698A (en) * 1992-08-26 1996-03-05 Ribozyme Pharmaceuticals, Inc. Method of isolating ribozyme targets
CA2135646A1 (en) * 1992-05-11 1993-11-25 Kenneth G. Draper Method and reagent for inhibiting viral replication
US5610052A (en) * 1992-08-26 1997-03-11 Ribozyme Pharmaceuticals Inc. Enzymatic RNA with activity to ras
US5972699A (en) * 1992-05-14 1999-10-26 Ribozyme Pharmaceuticals, Inc. Method and reagent for inhibiting herpes simplex virus replication
US5750390A (en) * 1992-08-26 1998-05-12 Ribozyme Pharmaceuticals, Inc. Method and reagent for treatment of diseases caused by expression of the bcl-2 gene
US5622854A (en) * 1992-05-14 1997-04-22 Ribozyme Pharmaceuticals Inc. Method and reagent for inhibiting T-cell leukemia virus replication
US5525468A (en) * 1992-05-14 1996-06-11 Ribozyme Pharmaceuticals, Inc. Assay for Ribozyme target site
US5989906A (en) * 1992-05-14 1999-11-23 Ribozyme Pharmaceuticals, Inc. Method and reagent for inhibiting P-glycoprotein (mdr-1-gene)
US5693535A (en) * 1992-05-14 1997-12-02 Ribozyme Pharmaceuticals, Inc. HIV targeted ribozymes
US6492512B1 (en) 1992-08-26 2002-12-10 Ribozyme Pharmaceuticals, Inc. Method and reagent for treatment of lung cancer and other malignancies caused by the deregulation of L-MYC gene expression
US5610054A (en) * 1992-05-14 1997-03-11 Ribozyme Pharmaceuticals, Inc. Enzymatic RNA molecule targeted against Hepatitis C virus
US6258585B1 (en) 1992-05-14 2001-07-10 Ribozyme Pharmaceuticals, Inc. Method and reagent for inhibiting influenza virus replication
JPH07509133A (ja) * 1992-07-17 1995-10-12 リボザイム・ファーマシューティカルズ・インコーポレイテッド 動物疾患の処置のための方法および剤
US6544755B1 (en) 1992-08-26 2003-04-08 Ribozyme Pharmaceuticals, Inc. Method and reagent for treatment of diseases by expression of the c-Myc gene
US5599704A (en) * 1992-08-26 1997-02-04 Ribozyme Pharmaceuticals, Inc. ErbB2/neu targeted ribozymes
US5646042A (en) * 1992-08-26 1997-07-08 Ribozyme Pharmaceuticals, Inc. C-myb targeted ribozymes
CA2144848A1 (en) * 1992-09-18 1994-03-31 H. Michael Shepard Gene therapy by retroviral vector with tumor suppressive gene
DE69334238D1 (de) 1992-09-25 2008-09-25 Aventis Pharma Sa Adenovirus vektoren für die übertragung fremder gene in zellen des zentralen nervensystems, insbesondere im gehirn
DE69331526T2 (de) 1992-11-18 2002-10-24 Arch Development Corp., Chicago Adenovirus gelenkter gen-transfer zum herz- und glatten vaskularen muskel
US5658780A (en) * 1992-12-07 1997-08-19 Ribozyme Pharmaceuticals, Inc. Rel a targeted ribozymes
US5616490A (en) * 1992-12-07 1997-04-01 Ribozyme Pharmaceuticals, Inc. Ribozymes targeted to TNF-α RNA
US5612215A (en) * 1992-12-07 1997-03-18 Ribozyme Pharmaceuticals, Inc. Stromelysin targeted ribozymes
US5837542A (en) * 1992-12-07 1998-11-17 Ribozyme Pharmaceuticals, Inc. Intercellular adhesion molecule-1 (ICAM-1) ribozymes
US5616488A (en) * 1992-12-07 1997-04-01 Ribozyme Pharmaceuticals, Inc. IL-5 targeted ribozymes
US5811300A (en) * 1992-12-07 1998-09-22 Ribozyme Pharmaceuticals, Inc. TNF-α ribozymes
AU5961094A (en) * 1992-12-31 1994-08-15 Texas Biotechnology Corporation Antisense molecules directed against a platelet derived growth factor receptor related gene
US5639655A (en) * 1993-01-19 1997-06-17 Ribozyme Pharmaceuticals, Inc. PML-RARA targeted ribozymes
US5496731A (en) * 1993-03-25 1996-03-05 Xu; Hong-Ji Broad-spectrum tumor suppressor genes, gene products and methods for tumor suppressor gene therapy
US5645829A (en) * 1993-06-18 1997-07-08 Beth Israel Hospital Association Mesothelial cell gene therapy
US5739309A (en) * 1993-07-19 1998-04-14 Gen-Probe Incorporated Enhancement of oligonucleotide inhibition of protein production, cell proliferation and / or multiplication of infectious disease pathogens
ATE239787T1 (de) * 1993-07-19 2003-05-15 Gen Probe Inc Oligonukleotide mit wirkung gegen den menschlichen immunodefiziens-virus
WO1995011301A1 (en) * 1993-10-19 1995-04-27 The Regents Of The University Of Michigan P53-mediated apoptosis
US5700657A (en) * 1993-12-13 1997-12-23 Genzyme Corporation Vectors and vector systems including genes encoding tumor suppressor proteins and producer cells transformed thereby
EP0750503A4 (de) * 1994-03-07 1999-07-21 Immusol Inc Ribozymtherapie für restenose
US5834440A (en) * 1994-03-07 1998-11-10 Immusol Incorporated Ribozyme therapy for the inhibition of restenosis
WO1995024477A1 (en) * 1994-03-08 1995-09-14 City Of Hope Human papillomavirus targeted ribozymes
US6103890A (en) * 1994-05-18 2000-08-15 Ribozyme Pharmaceuticals, Inc. Enzymatic nucleic acids that cleave C-fos
AUPM672594A0 (en) * 1994-07-08 1994-08-04 Royal Children's Hospital Research Foundation A method for the prophylaxis and/or treatment of proliferative and/or inflammatory skin disorders
AU4502096A (en) * 1994-11-11 1996-06-06 Arch Development Corporation A process of inhibiting non-neoplastic pathological cell proliferation
US5869040A (en) * 1995-06-07 1999-02-09 Biogen, Inc Gene therapy methods and compositions
US7888466B2 (en) 1996-01-11 2011-02-15 Human Genome Sciences, Inc. Human G-protein chemokine receptor HSATU68
EP0954222A4 (de) * 1996-04-10 2003-01-15 Univ Southern California Gentherapie zur proliferativen vitreoretinopathie
US6054467A (en) * 1996-07-05 2000-04-25 Sidney Kimmel Cancer Center Down-regulation of DNA repair to enhance sensitivity to P53-mediated apoptosis
WO1998001148A1 (en) 1996-07-09 1998-01-15 President And Fellows Of Harvard College Use of papillomavirus e2 protein in treating papillomavirus-infected cells and compositions containing the protein
US5958892A (en) 1996-07-30 1999-09-28 Board Of Regents, The University Of Texas System 2-methoxyestradiol-induced apoptosis in cancer cells
EP0925074A4 (de) 1996-09-06 2002-04-17 Univ Columbia Umkehr eines krebsphenotyps durch expressionsinhibierung von prostatatumor-induzierenden genen
US6057156A (en) 1997-01-31 2000-05-02 Robozyme Pharmaceuticals, Inc. Enzymatic nucleic acid treatment of diseases or conditions related to levels of epidermal growth factor receptors
KR20010072475A (ko) * 1998-08-13 2001-07-31 추후제출 재발협착증을 치료하기 위한 dna자임 및 치료 방법
AU1219400A (en) * 1998-10-22 2000-05-08 Duke University Methods of screening for risk of proliferative disease and methods for the treatment of proliferative disease
JP2003530309A (ja) * 1999-10-26 2003-10-14 イミューソル インコーポレイテッド 増殖性皮膚疾患又は増殖性眼疾患を治療するリボザイム療法
WO2002064612A2 (en) 2001-02-09 2002-08-22 Human Genome Sciences, Inc. Human g-protein chemokine receptor (ccr5) hdgnr10
WO2004097020A2 (en) * 2003-04-25 2004-11-11 Sirna Therapeutics, Inc. Rna interference mediated inhibition of map kinase gene expression
US9657294B2 (en) 2002-02-20 2017-05-23 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
US9181551B2 (en) 2002-02-20 2015-11-10 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
AU2004206250B8 (en) 2003-01-21 2009-09-17 Bristol-Myers Squibb Company Polynucleotide encoding a novel acyl coenzyme a, monoacylglycerol acyltransferase-3 (MGAT3), and uses thereof
WO2006128063A2 (en) * 2005-05-25 2006-11-30 Irm Llc Methods and compositions for inhibiting glioma growth
US7572618B2 (en) 2006-06-30 2009-08-11 Bristol-Myers Squibb Company Polynucleotides encoding novel PCSK9 variants
WO2012058210A1 (en) 2010-10-29 2012-05-03 Merck Sharp & Dohme Corp. RNA INTERFERENCE MEDIATED INHIBITION OF GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACIDS (siNA)

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4740463A (en) * 1984-04-13 1988-04-26 Massachusetts Institute Of Technology Methods and artificial genes for antagonizing the function of an oncogene
EP0398955B1 (de) * 1988-01-21 1998-07-08 MASSACHUSETTS EYE & EAR INFIRMARY Diagnose von retinoblastoma
WO1989012687A1 (en) * 1988-06-16 1989-12-28 La Jolla Cancer Research Foundation Retinoic acid receptor
US5098890A (en) * 1988-11-07 1992-03-24 Temple University-Of The Commonwealth System Of Higher Education Antisence oligonucleotides to c-myb proto-oncogene and uses thereof
CA2006008C (en) * 1988-12-20 2000-02-15 Donald J. Kessler Method for making synthetic oligonucleotides which bind specifically to target sites on duplex dna molecules, by forming a colinear triplex, the synthetic oligonucleotides and methods of use
DE69110034T2 (de) * 1990-03-14 1995-10-05 Washington Res Found Methoden und zusammensetzungen zur behandlung von bösartigen entartungen, die in zusammenhang mit einer proteinkinase stehen.
AU7152191A (en) * 1990-06-07 1991-12-31 City Of Hope Ribozyme mediated reversal of transformation by cleavage of the hras oncogene rna
NO312681B1 (no) * 1990-08-24 2002-06-17 Univ California Fremgangsmåte for fremstilling av en farmasöytisk blanding med suppresiv virkning/aktivitet
US5262321A (en) * 1991-05-31 1993-11-16 Dana-Farber Cancer Institute DNA encoding p107 tumor suppressor

Also Published As

Publication number Publication date
EP0960941A1 (de) 1999-12-01
IE20010427A1 (en) 2003-03-05
PT97316A (pt) 1991-12-31
EP0527804B1 (de) 2000-03-15
IE911115A1 (en) 1991-10-23
NO923917D0 (no) 1992-10-08
GR3033695T3 (en) 2000-10-31
KR100304033B1 (ko) 2001-12-15
FI924574A7 (fi) 1992-10-09
DE69132047T2 (de) 2000-07-13
ZA912491B (en) 1993-02-24
JPH05507067A (ja) 1993-10-14
PT97316B (pt) 1998-08-31
FI924574L (fi) 1992-10-09
EP0527804A4 (en) 1993-07-14
KR937000652A (ko) 1993-03-15
DK0527804T3 (da) 2000-06-05
NO923917L (no) 1992-12-01
IL97774A0 (en) 1992-06-21
DE69132047D1 (de) 2000-04-20
WO1991015580A1 (en) 1991-10-17
AU7750191A (en) 1991-10-30
EP0527804A1 (de) 1993-02-24
CN1056427A (zh) 1991-11-27
CN1057121C (zh) 2000-10-04
FI924574A0 (fi) 1992-10-09
AU3319495A (en) 1996-03-07
AU9048698A (en) 1999-01-14
ES2143463T3 (es) 2000-05-16
CA2079903A1 (en) 1991-10-11

Similar Documents

Publication Publication Date Title
DE69132047D1 (de) Gentherapie gegen krankheiten die die zellteilung betreffen
CY1107584T1 (el) Μεθοδοι και συνθεσεις για την προληψη και θepαπεια της αναιμιας
ATE100447T1 (de) 19-nor-vitamin-d-derivate.
NL189092C (nl) Hybride menselijke leukocytinterferons, dubbelstrengs dna dat hiervoor codeert, expressievector, transformant micro-organisme, werkwijzen ter bereiding daarvan en farmaceutisch preparaat.
ATE197670T1 (de) Parenterales busulfan zur behandlung von malignen krankheiten
NO870241D0 (no) Hypoglykemiske tiazolidindioner.
NO890259D0 (no) Fremgangsmaate for fremstilling av terapeutisk aktive etylfenoksyacetamider.
HUP9800028A2 (hu) Több tumor esetében rendellenes sejtszaporodás előidézésében közrejátszó gének
JPS5756427A (en) Medicine containing 2-phenyl-1,2-benzisoselenazole- 3(2h)-one
MX9301700A (es) Muteinas del factor de necrosis tumoral humano, procedimiento para su preparacion y composiciones farmaceuticas que las contienen.
ATE56138T1 (de) Perfluorkohlenwasserstoffe als vehikel zur verabreichung von arzneimitteln.
NO912142D0 (no) Foradditiv for fisk.
DE69314586D1 (de) Arzneimittelzusammensetzung enthaltend TCF-II
FI810380L (fi) Fenylpiperazinderivat av 1,3,4-oxadiazolylfenoler deras framstaellning och dessa innehaollande terapeutiska aemnen
DE3572441D1 (en) Use of interferon gamma (ifn-gamma) for the production of preparations for treating rheumatic diseases
WO2024006821A3 (en) Methods of treating a tumor
AU7336687A (en) Treatment of basal cell carcinoma intralesionally with recombinant human alpha interferon
ATE140928T1 (de) Proteine, die die expression von vertebraten-mhc- klasse-ii-genen regulieren, dafür kodierende dna- sequenzen und pharmazeutische zusammensetzungen
DE3374066D1 (en) N-acyl derivatives of peptides, their manufacture and use in combating diseases and means therefor
WO2024006804A3 (en) Methods of administering a sting agonist
IT8068350A0 (it) Composizione farmaceutica per il trattamento di malattie microvasco lari
DE59405189D1 (de) Neues diphenylhexen

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee